Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes

Life Sciences [q-bio] Microbiology and Parasitology Bacteriology Life Sciences [q-bio] Microbiology and Parasitology Virology Life Sciences [q-bio] Microbiology and Parasitology Parasitology Life Sciences [q-bio] Human health and pathology Cardiology and cardiovascular system Life Sciences [q-bio] Human health and pathology Emerging diseases Life Sciences [q-bio] Human health and pathology Infectious diseases

Isabelle COMBE : Connect in order to contact the contributor

https://hal-amu.archives-ouvertes.fr/hal-03216101

Submitted on : Monday, May 3, 2021-5:24:23 PM

Last modification on : Monday, April 11, 2022-10:36:13 AM

Dates and versions

hal-03216101 , version 1 (03-05-2021)

Identifiers

HAL Id : hal-03216101 , version 1
DOI : 10.1016/j.ijantimicag.2020.106239
PUBMED : 33408029
PUBMEDCENTRAL : PMC7779264

Cite

Philippe Gautret, van Thuan Hoang, Jean-Christophe Lagier, Didier Raoult. Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes. International Journal of Antimicrobial Agents, 2021, 57 (1), pp.106239. ⟨10.1016/j.ijantimicag.2020.106239⟩. ⟨hal-03216101⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

CNRS UNIV-AMU INCIAM

19 View

0 Download